There are so many resources available for you to learn more about clinical trials, participating in studies, how to recognize symptoms, care for loved ones with mental health conditions, and so much more. We have created a list of blog posts, videos, and information to get you connected with a clinical trial professional who can answer any questions you may have. Be sure to check out our blog below!
Five Ways to Help Someone with Depression
Nine Symptoms of BPD
11 Symptoms of PTSD
Attend Brain Awareness Week
Learn more about our social anxiety study
Learn More About Clinical Trials
Are you considering being part of a clinical trial? Learn more about what it looks like to participate in a clinical trial along with the process. Those who qualify will receive all study-required medical care at no cost. Health insurance is not required.
OCD Clinical Trial Testimonial
Adults with OCD who are not satisfied with their current medication may be eligible to participate in a study with an investigational medication that would be added to their current medication. Contact us to learn more!
Alzheimer’s Clinical Trial Testimonial
Is someone you care for with Alzheimer’s dementia exhibiting excessive motor activity, verbal and/or physical aggression? If so, they may qualify for the ASPECT clinical research study. The purpose of this study is to evaluate the safety and effectiveness of
an investigational drug for agitation associated with Alzheimer’s dementia. Contact us to learn more!
Migraine Clinical Trial
The Periscope Study is Looking to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics or Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents. Contact us to learn more!
Alzheimer’s Clinical Trial
The ASPECTTM clinical research study is evaluating an investigational drug for agitation associated with Alzheimer’s dementia and participants between the ages of 50 and 90 are needed. Those who qualify will receive study-required medical care at no cost. Health insurance is not required. Contact us to learn more!
3998 Vista Way, Suite 100
Oceanside, CA 92056
Contact us today or follow us on social media!
Click to see if you qualify to participate in one of our clinical trials or give us a call!
A biomarker may be used as a test to see how a person will respond to a certain drug, or how they will tolerate a certain treatment.
The iMatchDepression program is led by Denovo Biopharma with the goal to help people with depression who do not respond well to current treatment options. A goal of the DB104-01 study is to help develop personalized medicine for certain people with depression who have a specific gene variant (genotype) referred to as biomarker DGM4. If you decide to enroll in iMatchDepression, your DGM4 biomarker status will be determined by testing a sample of your saliva. Based on the results, you may be invited to participate in the DB104-01 study. There is no cost to join the Registry.
Copyright © 2022 All Rights Reserved. Powered by Denovo Biopharma LLC
Excepted from “The 988 Mental Health Hotline Is Coming. Is America Ready?” from US News and World Report
988, the mental health equivalent of 911, is about to launch across the United States.
As of July 16th, a new 988 number is available 24/7 for Americans dealing with a mental health crisis. It’s akin to 911, long used to get help for medical emergencies.
The new code will replace the 10-digit number currently used to reach the National Suicide Prevention Lifeline, which was established in 2005. Health officials expect the easy-to-remember 988 to spur a surge in calls.
The trouble is, few jurisdictions are ready for that, according to the new study, by the nonprofit research organization RAND Corp.
“At the service level, the 988 transition is a simple number change,” said Ryan McBain, a RAND policy researcher who co-led the study. But on the ground, McBain said, it’s a different story.
For one, local crisis centers need enough counselors to handle any influx of calls. Beyond that, some callers will need additional in-person help.
Yet, the study found, many jurisdictions lack such resources. It surveyed 180 state, regional and county health officials, and found that only half said their jurisdiction had short-term “crisis stabilization” services to which callers could be directed.
Even fewer — 28% — had urgent care units that could be dispatched to people in urgent need. Meanwhile, only 22% had call centers that could schedule mental health appointments on behalf of people who wanted them.
On top of those shortfalls, most local hotlines did not offer text or online chat options. That’s a key gap, McBain said, since teenagers and young adults often prefer those modes of communication.
Overall, McBain said, the findings confirm the concerns of many mental health experts: Jurisdictions have not had the time or resources to prepare for the 988 rollout.
The 988 code was authorized by Congress in 2020, with the intent of giving Americans an easier way to reach the National Suicide Prevention Lifeline. The Lifeline is a network of almost 200 crisis centers throughout the United States. When people call the national number, they are connected with the center closest to them to speak with a trained counselor and, if needed, get help finding local resources.
“It’s when it comes to referral to local services that things will get more complicated,” said Trestman, chair of the American Psychiatric Association’s Council on Healthcare Systems and Financing.
To read the full article, visit US News and World Report.
The STARR Coalition | phone: 501-725-8890 | www.thestarr.org
Project RockSTARR is a donation program that puts sponsors’ advocacy support to work, building relationships between advocacy and research at the local level, and supporting community efforts to help those living with mental illnesses.
The RockSTARR program is simple: when a volunteer screens for a study, they are given information about the advocacy organizations and resources within their community. At that moment, the volunteer is given the opportunity to allocate a donation (provided by the Sponsor) to a local advocacy group.
The Voice of the American Psychiatric Association and the Psychiatric Community
Youth With Migraines Twice as Likely to Have Anxiety, Depression
Children and adolescents who get migraines may have a greater risk of experiencing anxiety and depressive symptoms and disorders compared with their peers who do not get migraines, according to a report published in JAMA Pediatrics.
“The association between migraine and anxiety and depressive symptoms and disorders is likely bidirectional and multifactorial,” wrote Katherine Falla, M.D., of the University of Calgary and colleagues. “The experience of pain and internalizing symptoms may result in mutually reinforcing behaviors, such as reduced sleep and withdrawal from activities, and mutually reinforcing cognitive patterns, such as negativity bias and attention bias.”
Falla and colleagues conducted a systematic review of case-control, cohort, and cross-sectional studies that assessed the association between internalizing symptoms and/or disorders and experiences of migraines in children and adolescents 18 years or younger. They searched MEDLINE, Embase, PsycINFO, and CINAHL databases for studies that assessed symptoms and disorders on the spectrum of anxiety disorders, depressive disorders, and trauma- and stressor-related disorders, as defined in DSM-5. The authors reviewed 80 studies, and 51 included data that were able to be pooled in a meta-analysis.
Anxiety and depressive symptoms were significantly higher in children and adolescents who had migraines compared with controls. Further, youth who experienced migraines were about twice as likely to have an anxiety or depressive disorder compared with those without migraines. In studies that compared children and adolescents who experienced migraines with those who had other headache disorders (tension-type headaches, new daily persistent headaches), no significant differences emerged for internalizing symptoms between the two groups.
Three studies assessed the longitudinal association between anxiety and depressive symptoms and migraine outcomes, and these found that higher anxiety and depressive symptoms were associated with higher headache frequencies at follow up, which ranged from one to four months.
This study “is one more piece of evidence supporting our need to address and improve mental health care for youth,” wrote Jessica Hauser Chatterjee, M.D., Ph.D., and Heidi Blume, M.D., M.P.H., of the Seattle Children’s Research Institute in an accompanying commentary. “It is likely that youth with migraine are particularly vulnerable to experiencing significant adverse effects and poor outcomes related to mental health disorders, but more work is needed to investigate these associations. There needs to be a radical evolution in how the medical and governmental systems support mental health of youth with migraine, other headache syndromes, neurological disorders, and other chronic health problems.”
For related information, see the Psychiatric News article “Psychiatrists Have a Role in Managing Pediatric Pain.”
Don’t miss out! To learn about newly posted articles in Psychiatric News, please sign up here.